• Mashup Score: 1
    To Stent or Not to Stent in Ischemic Heart Failure: The REVIVED-BCIS2 Trial - American College of Cardiology - 8 month(s) ago

    The question of revascularization in patients with heart failure (HF) and severe left ventricular (LV) systolic dysfunction is almost as old as the specialty itself. 1 The STICH (Surgical Treatment for Ischemic Heart Failure) trial did not demonstrate a survival benefit of coronary artery bypass grafting at 5 years in patients with ischemic cardiomyopathy (ICM). 2 Percutaneous coronary intervention (PCI) has not been studied in patients with severe LV dysfunction. The REVIVED-BCIS2 (Revascularization for

    Source: www.acc.org
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of nrajag
      nrajag

      Any benefit to revascularization in heart failure? Analysis of REVIVED-BCIS trial by @MeganPelter #revascularization #stent #HF #heartfailure https://t.co/EcbqROKiPp

  • Mashup Score: 1
    InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial - 10 month(s) ago

    June 26, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption(IDE) clinical trial, designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system.  Marvin Slosman, chief executive officer of InspireMD,…

    Source: DAIC
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DAICeditor
      DAICeditor

      @DAICeditor @InspireMD InspireMD announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption(#IDE) #clinical_trial, designed to support potential U.S. marketing approval of the #CGuard_Prime #EPS #stent system: https://t.co/Ty1FgoCKM5

Load More